You have accessJournal of UrologyCME1 Apr 2023MP79-15 ERECTILE FUNCTION RECOVERY AMONG YOUNG MEN WITH ERECTILE DYSFUNCTION ON OaD TADALAFIL 5 MG: FINDINGS FROM A REAL-LIFE STUDY Edoardo Pozzi, Federico Belladelli, Giuseppe Fallara, Simone Cilio, Christian Corsini, Alessandro Bertini, Massimiliano Raffo, Fausto Negri, Ludovica Cella, Margherita Fantin, Francesco Lanzaro, Luigi Candela, Paolo Capogrosso, Luca Boeri, Alessia d'Arma, Francesco Montorsi, and Andrea Salonia Edoardo PozziEdoardo Pozzi More articles by this author , Federico BelladelliFederico Belladelli More articles by this author , Giuseppe FallaraGiuseppe Fallara More articles by this author , Simone CilioSimone Cilio More articles by this author , Christian CorsiniChristian Corsini More articles by this author , Alessandro BertiniAlessandro Bertini More articles by this author , Massimiliano RaffoMassimiliano Raffo More articles by this author , Fausto NegriFausto Negri More articles by this author , Ludovica CellaLudovica Cella More articles by this author , Margherita FantinMargherita Fantin More articles by this author , Francesco LanzaroFrancesco Lanzaro More articles by this author , Luigi CandelaLuigi Candela More articles by this author , Paolo CapogrossoPaolo Capogrosso More articles by this author , Luca BoeriLuca Boeri More articles by this author , Alessia d'Arma Alessia d'Arma More articles by this author , Francesco MontorsiFrancesco Montorsi More articles by this author , and Andrea SaloniaAndrea Salonia More articles by this author View All Author Informationhttps://doi.org/10.1097/JU.0000000000003356.15AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION AND OBJECTIVE: Daily tadalafil 5 mg provides a valuable alternative to on-demand tadalafil for men who prefer spontaneous to scheduled sexual attempts. We investigated the rate of and the clinical factors associated with erectile function (EF) recovery after discontinuation of 5 mg tadalafil OaD in a cohort of young men seeking medical help for ED as primary complaint. METHODS: Data from 96 consecutive young patients (<50 yr) with ED and prescribed with 5 mg tadalafil OaD were analysed. All patients were diagnosed with psychogenic ED after a comprehensive clinical evaluation including penile duplex ultrasound and hormonal profile assessment. All completed the International IIEF at baseline. Length of treatment varied from 1 to 12 months according to clinical judgement. EF recovery was assessed after 2 weeks from treatment discontinuation and defined as IIEF-EF >21 after daily 5 mg tadalafil discontinuation. Patients without EF recovery were classified as tadalafil OaD non-responders. Cox-regression models tested the association between patients' baseline characteristics and the probability of EF recovery after treatment discontinuation. Kaplan-Meier analyses estimated the probability of EF recovery over time. RESULTS: Median (IQR) age was 39 (32-45) yr. Of all, 82 (85.4%) achieved EF recovery at treatment discontinuation, whilst 14 (14.6%) were identified as non-responders. Median treatment length was 3 (2-11) months. Most common treatment-related adverse effect was headache in 9 (9.4%) patients. Non-responders were older (43 vs. 38, p=0.03), with higher BMI (25.54 vs. 23.6, p=0.04) and depicted lower IIEF-EF scores at baseline (12 vs. 15, p=0.02) than responders. No differences in terms of comorbidities (CC≥1), smoking, alcohol consumption and regular physical exercise were detected. Kaplan Meier estimates of EF recovery at 3, 6 and 12 months, were 43% (95%CI: 41-62), 60% (95%CI: 49-69) and 75% (95%CI: 64-83), respectively (Figure 1). Younger age (HR: 0.95; 95% CI: 0.92-0.99, p=0.01) was associated with EF recovery after adjusting for baseline EF, BMI, smoking and CCI≥1. CONCLUSIONS: Almost one out of two young ED patients prescribed with tadalafil OaD achieved full EF recovery within 3 months of treatment. Younger patients have higher probability of EF recovery with daily 5 mg tadalafil therapy. Source of Funding: NA © 2023 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 209Issue Supplement 4April 2023Page: e1147 Advertisement Copyright & Permissions© 2023 by American Urological Association Education and Research, Inc.MetricsAuthor Information Edoardo Pozzi More articles by this author Federico Belladelli More articles by this author Giuseppe Fallara More articles by this author Simone Cilio More articles by this author Christian Corsini More articles by this author Alessandro Bertini More articles by this author Massimiliano Raffo More articles by this author Fausto Negri More articles by this author Ludovica Cella More articles by this author Margherita Fantin More articles by this author Francesco Lanzaro More articles by this author Luigi Candela More articles by this author Paolo Capogrosso More articles by this author Luca Boeri More articles by this author Alessia d'Arma More articles by this author Francesco Montorsi More articles by this author Andrea Salonia More articles by this author Expand All Advertisement PDF downloadLoading ...